Pharma Exclusives Pressreleases
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
Monday, June 16, 2025Roche announced today its decision to proceed with Phase III development of prasinezumab an investigational antialphasynuclein antibody in earlystage Parkinsons disease This decision is informed by data
Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
Monday, June 16, 2025Rocheannounced today new dosing restrictions effective immediately for ELEVIDYS delandistrogene moxeparvovec for nonambulatory Duchenne muscular dystrophy DMD patients irrespective of age
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
Monday, June 16, 2025Teva Pharmaceutical Industries Ltd and Shanghai Fosun Pharmaceutical Group Co Ltd today announced that the companies through their respective subsidiaries have entered a strategic partnership for the development
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
Friday, June 13, 2025Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase development in weight management based on completed clinical studies The decision to advance subcutaneous and oral
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
Tuesday, June 10, 2025RenaissThera Private Limited RenaissThera a Bengalurubased biotechnology company announced a major milestone in its obesity drug discovery program targeting the glucosedependent insulinotropic polypeptide receptor
Osteolabs GmbH and labor team w ag Announce Sales Partnership for Switzerland and Liechtenstein
Tuesday, June 10, 2025Osteolabs GmbH a German biotech company specializing in innovative diagnostic solutions for calciumrelated metabolic disorders and labor team one of the leading medical laboratories in Switzerland are pleased to announce a new strategic partnership
Simultaneous treatment start with Finerenone and SGLT-2-inhibitor demonstrated positive data in patients with CKD associated with type 2 diabetes
Thursday, June 05, 2025Results of the Phase II study CONFIDENCE demonstrate that simultaneous initiation of finerenone and an SGLTinhibitor SGLTi led to significant reductions in urine albumintocreatinine ratio UACR versus either agent alone in patients with chronic kidney...
U.S. FDA approves third indication of Bayer blockbuster Nubeqa™ (darolutamide) for patients with advanced prostate cancer
Wednesday, June 04, 2025Bayer announced today that the US Food and Drug Administration FDA has approved its oral androgen receptor inhibitor ARi Nubeqa darolutamide in combination with androgen deprivation therapy ADT for use in patients with metastatic castrationsensitive...
Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)
Wednesday, June 04, 2025Rocheannounced today that the European Commission EC has approved a label extension for Evrysdi risdiplam to include a new roomtemperature stable tablet for people living with spinal muscular atrophy SMA
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
Tuesday, June 03, 2025Zealand Pharma AS a biotechnology company focused on the discovery and development of innovative peptidebased medicines today announced the submission of a Marketing Authorization Application MAA to the European Medicines
